LOS ANGELES--(BUSINESS WIRE)--Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY. ...

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm represents both individual and institutional investors in complex litigation across various courts [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [2][4]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [2]. - The firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations and Stock Performance - The complaint against Unicycive alleges that the company and its executives made false or misleading statements regarding their readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of their OLC NDA [4]. - Following a press release on June 10, 2025, regarding FDA deficiencies, Unicycive's stock price dropped by $3.68 per share, a decline of 40.89%, closing at $5.32 per share [5]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock fell by $2.03 per share, or 29.85%, closing at $4.77 per share [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 between March 29, 2024, and June 27, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [7].

Group 1 - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding potential legal matters [1]

Group 1 - The Schall Law Firm has initiated a class action lawsuit against Unicycive Therapeutics, Inc. for violations of the Securities Exchange Act of 1934 [1][4] - The class period for the lawsuit is defined as between March 29, 2024, and June 27, 2025, during which investors are encouraged to participate if they suffered losses [2] - The complaint alleges that Unicycive made false and misleading statements regarding its FDA manufacturing compliance and the likelihood of FDA approval for its treatment OLC [4] Group 2 - Investors are advised to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3] - The class has not yet been certified, meaning that until certification occurs, investors are not represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Unicycive between March 29, 2024, and June 27, 2025, to contact them for legal options [1]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA due to the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members, overseeing the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - It is alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [2]. - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

Group 1 - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. [1]

Group 1 - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding potential legal matters [1]

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - It is alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [2]. - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].